56810 Federal Register / Vol. 76, No. 178 / Wednesday, September 14, 2011 / Notices 

If you want to submit confidential 

business information as part of your 

comment, but do not want it to be 

posted online or made available in the 

public docket, you must include the 

phrase ‘‘Confidential Business 

Information’’ in the first paragraph of 

your comment. You must also 

prominently identify confidential 

business information to be redacted 

within the comment. If a comment has 

so much confidential business 

information that it cannot be effectively 

redacted, all or part of that comment 

may not be posted online or made 

available in the public docket. 

Personal identifying information and 

confidential business information 

identified and located as set forth above 

will be redacted, and the comment, in 

redacted form, will be posted online and 

placed in the DEA’s public docket file. 

Please note that the Freedom of 

Information Act applies to all comments 

received. If you wish to inspect the 

agency’s public docket file in person by 

appointment, please see the FOR

FURTHER INFORMATION CONTACT

paragraph. 

Background 

The proposed 2012 assessment of 

annual needs represents those quantities 

of ephedrine, pseudoephedrine, and 

phenylpropanolamine which may be 

manufactured domestically and/or 

imported into the United States to 

provide adequate supplies of each 

chemical to meet the estimated medical, 

scientific, research, and industrial needs 

of the United States, lawful export 

requirements, and the establishment 

and maintenance of reserve stocks of 

such chemicals. 

In proposing the 2012 assessment of 

annual needs for ephedrine, 

pseudoephedrine, and 

phenylpropanolamine, DEA has taken 

into account the criteria that DEA is 

required to consider in accordance with 

21 U.S.C. 826(a) and 21 CFR 1315.11. 

DEA proposes the assessment of annual 

needs for 2012 by considering (1) Total 

net disposal of the chemical by all 

manufacturers and importers during the 

current and two preceding years; (2) 

trends in the national rate of net 

disposals of each chemical; (3) total 

actual (or estimated) inventories of the 

chemical and of all substances 

manufactured from the chemical, and 

trends in inventory accumulation; (4) 

projected demand for each chemical as 

indicated by procurement and import 

quotas requested pursuant to 21 CFR 

1315.32; and (5) other factors affecting 

the medical, scientific, research, 

industrial, and importation needs in the 

United States, lawful export 

requirements, and reserve stocks, as the 

Administrator finds relevant. 

Other factors that DEA considered 

include trends as derived from 

information provided in applications for 

import, manufacturing, and 

procurement quotas and in import and 

export declarations. The inventory, 

acquisition (purchases), and disposition 

(sales) data as provided by DEA 

registered manufacturers and importers 

reflects the most current information 

available to DEA at the time of 

publication of this Notice. DEA notes, 

pursuant to 21 CFR 1315.13 the DEA 

may adjust the assessments of annual 

needs for ephedrine, pseudoephedrine 

or phenylpropanolamine that has been 

previously fixed pursuant to 21 CFR 

1315.11. 

Analysis 

In determining the 2012 assessments, 

DEA has used the calculation 

methodology described previously in 

the 2010 and 2011 assessment of annual 

needs (74 FR 60294 and 75 FR 79407 

respectively). Additionally, DEA 

considered the total net disposals (i.e. 

sales) of these List I chemicals for the 

current and preceding two years, actual 

and estimated inventories, projected 

demand (2012), industrial use, and 

export requirements from data provided 

by DEA registered manufacturers and 

importers in procurement quota 

applications (DEA 250), manufacturing 

quota applications (DEA 189), import 

quota applications (DEA 488), and 

declarations for import and export. DEA 

notes that the inventory, acquisition 

(purchases) and disposition (sales) data 

provided by DEA registered 

manufacturers and importers reflects the 

most current information available. 

In finalizing the 2012 assessment of 

annual needs for ephedrine, 

pseudoephedrine, and 

phenylpropanolamine, DEA will 

consider the information contained in 

additional applications for 2012 import, 

manufacturing, and procurement quotas 

from DEA registered manufacturers and 

importers that DEA receives after the 

date of drafting this notice, June 22, 

2011, as well as the comments that DEA 

receives in response to this proposal. 

The Administrator, therefore, 

proposes the following assessment of 

annual needs for the List I chemicals 

ephedrine, pseudoephedrine, and 

phenylpropanolamine for 2012, 

expressed in kilograms of anhydrous 

base: 

List I chemicals 

Proposed year 

2012 

assessment of 

annual needs 

(kg) 

Ephedrine (for sale) .............. 3,400 

Phenylpropanolamine (for 

sale) .................................. 5,200 

Pseudoephedrine (for sale) .. 240,000 

Phenylpropanolamine (for 

conversion) ........................ 26,200 

Ephedrine (for conversion) ... 12,000 

Comments 

Pursuant to 21 CFR 1315.11, any 

interested person may submit written 

comments on or objections to these 

proposed determinations. Based on 

comments received in response to this 

Notice, the Administrator may hold a 

public hearing on one or more issues 

raised. In the event the Administrator 

decides in her sole discretion to hold 

such a hearing, the Administrator will 

publish a notice of any such hearing in 

the Federal Register. After 

consideration of any comments and 

after a hearing, if one is held, the 

Administrator will publish in the 

Federal Register a Final Order 

determining the assessment of annual 

needs for 2012 of ephedrine, 

pseudoephedrine, and 

phenylpropanolamine. 

Dated: September 1, 2011. 

Michele M. Leonhart, 

Administrator. 

[FR Doc. 2011–23505 Filed 9–13–11; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–343R] 

Controlled Substances: 2011 Proposed 

Aggregate Production Quotas 

AGENCY: Drug Enforcement 

Administration (DEA), Department of 

Justice. 

ACTION: Notice with request for 

comments. 

SUMMARY: This notice proposes to adjust 

the 2011 aggregate production quotas for 

several controlled substances in 

schedules I and II of the Controlled 

Substances Act (CSA) and separately 

proposes to establish aggregate 

production quotas for five synthetic 

cannabinoids temporarily controlled in 

Schedule I. 

DATES: Electronic comments must be 

submitted and written comments must 

mstockstill on DSK4VPTVN1PROD with NOTICES

Federal Register / Vol. 76, No. 178 / Wednesday, September 14, 2011 / Notices 56811 

be postmarked on or before October 14, 

2011. Commenters should be aware that 

the electronic Federal Docket 

Management System will not accept 

comments after midnight Eastern Time 

on the last day of the comment period. 

ADDRESSES: To ensure proper handling 

of comments, please reference ‘‘Docket 

No. DEA–343R’’ on all electronic and 

written correspondence. DEA 

encourages all comments be submitted 

electronically through http:// 

www.regulations.gov using the 

electronic comment form provided on 

that site. An electronic copy of this 

document is also available at the 

http://www.regulations.gov Web site for 

easy reference. Paper comments that 

duplicate the electronic submission are 

not necessary as all comments 

submitted to http://www.regulations.gov 

will be posted for public review and are 

part of the official docket record. Should 

you, however, wish to submit written 

comments via regular or express mail, 

they should be sent to the Drug 

Enforcement Administration, Attention: 

DEA Federal Register Representative/ 

ODL, 8701 Morrissette Drive, 

Springfield, VA 22152. 

FOR FURTHER INFORMATION CONTACT: 

Christine A. Sannerud, Ph.D., Chief, UN 

Reporting and Quota Section, Drug 

Enforcement Administration, 8701 

Morrissette Drive, Springfield, VA 

22152, Telephone: (202) 307–7184. 

SUPPLEMENTARY INFORMATION: 

Posting of Public Comments 

Please note that all comments 

received are considered part of the 

public record and made available for 

public inspection online at http:// 

www.regulations.gov and in the DEA’s 

public docket. Such information 

includes personal identifying 

information (such as your name, 

address, etc.) voluntarily submitted by 

the commenter. 

If you want to submit personal 

identifying information (such as your 

name, address, etc.) as part of your 

comment, but do not want it to be 

posted online or made available in the 

public docket, you must include the 

phrase ‘‘PERSONAL IDENTIFYING 

INFORMATION’’ in the first paragraph 

of your comment. You must also place 

all the personal identifying information 

you do not want posted online or made 

available in the public docket in the first 

paragraph of your comment and identify 

what information you want redacted. 

If you want to submit confidential 

business information as part of your 

comment, but do not want it to be 

posted online or made available in the 

public docket, you must include the 

phrase ‘‘CONFIDENTIAL BUSINESS 

INFORMATION’’ in the first paragraph 

of your comment. You must also 

prominently identify confidential 

business information to be redacted 

within the comment. If a comment has 

so much confidential business 

information that it cannot be effectively 

redacted, all or part of that comment 

may not be posted online or made 

available in the public docket. 

Personal identifying information and 

confidential business information 

identified and located as set forth above 

will be redacted, and the comment, in 

redacted form, will be posted online and 

placed in the DEA’s public docket file. 

Please note that the Freedom of 

Information Act applies to all comments 

received. If you wish to inspect the 

agency’s public docket file in person by 

appointment, please see the FOR

FURTHER INFORMATION CONTACT

paragraph. 

Background 

Section 306 of the CSA (21 U.S.C. 

826) requires that the Attorney General 

establish aggregate production quotas 

for each basic class of controlled 

substance listed in Schedules I and II. 

This responsibility has been delegated 

to the Administrator of the DEA by 

28 CFR 0.100. On September 15, 2010, 

a notice of proposed 2011 aggregate 

production quotas for certain controlled 

substances in schedules I and II was 

published in the Federal Register 

(75 FR 56137). That notice stipulated 

that the Administrator would adjust, as 

needed, the quotas in 2011 as provided 

for in 21 CFR 1303.13. The 2011 

established aggregate production quotas 

were subsequently published in the 

Federal Register (75 FR 79404) on 

December 20, 2010. 

Additionally, on March 1, 2011, the 

DEA Administrator published a Final 

Order which temporarily placed five 

synthetic cannabinoids in schedule I: 

1-[2-(4-Morpholinyl)ethyl]-3-(1- 

naphthoyl)indole (JWH-200); 1-Butyl-3- 

(1-naphthoyl)indole (JWH-073); 1- 

Pentyl-3-(1-naphthoyl)indole (JWH018); 5-(1,1-Dimethylheptyl)-2-[(1R,3S)- 

3-hydroxycyclohexyl]-phenol (CP47,497); and 5-(1,1-Dimethyloctyl)-2- 

[(1R,3S)-3-hydroxycyclohexyl]-phenol 

(cannabicyclohexanol; CP-47,497 C8 

homologue) (76 FR 11075). That Final 

Order stated that quotas for the five 

substances would be ‘‘established based 

on registrations granted and quota 

applications received pursuant to part 

1303 of Title 21 of the Code of Federal 

Regulations.’’ 76 FR 11075. Aggregate 

productions quotas for these 

temporarily scheduled substances have 

not previously been established. 

Analysis for Proposed Revised 2011 

Aggregate Production Quotas 

DEA now proposes to adjust the 

established 2011 aggregate production 

quotas for some schedule I and II 

controlled substances. In proposing the 

adjustment, DEA has taken into account 

the criteria that DEA is required to 

consider in accordance with 21 CFR 

1303.13. DEA proposes the adjustment 

of the aggregate production quotas for 

basic classes of schedule I and II 

controlled substances by considering 

(1) Changes in demand for the class, 

changes in the national rate of net 

disposal for the class, and changes in 

the rate of net disposal by the registrants 

holding individual manufacturing 

quotas for the class; (2) whether any 

increased demand or changes in the 

national and/or individual rates of net 

disposal are temporary, short term, or 

long term; (3) whether any increased 

demand can be met through existing 

inventories, increased individual 

manufacturing quotas, or increased 

importation without increasing the 

aggregate production quota; (4) whether 

any decreased demand will result in 

excessive inventory accumulation by all 

persons registered to handle the class; 

and (5) other factors affecting the 

medical, scientific, research, and 

industrial needs in the United States 

and lawful export requirements, as the 

Administrator finds relevant. 

In determining whether to propose 

adjustments to the 2011 aggregate 

production quotas, DEA considered 

updated information obtained from 

2010 year-end inventories, 2010 

disposition data submitted by quota 

applicants, estimates of the medical 

needs of the United States, product 

development, and other information 

made available to DEA after the initial 

aggregate production quotas had been 

established. The Administrator, 

therefore, proposes to adjust the 2011 

aggregate production quotas for some 

schedule I and II controlled substances, 

expressed in grams of anhydrous acid or 

base, as follows: 

mstockstill on DSK4VPTVN1PROD with NOTICES

56812 Federal Register / Vol. 76, No. 178 / Wednesday, September 14, 2011 / Notices 

Basic class–schedule I 

Previously established initial 

2011 quotas 

Proposed 

adjusted 

2011 quotas 

1-Methyl-4-phenyl-4-propionoxypiperidine .................................................................................... 2 g No Change. 

2,5-Dimethoxyamphetamine .......................................................................................................... 2 g No Change. 

2,5-Dimethoxy-4-ethylamphetamine (DOET) ................................................................................ 2 g No Change. 

2,5-Dimethoxy-4-n-propylthiophenethylamine ............................................................................... 2 g No Change. 

3-Methylfentanyl ............................................................................................................................ 2 g No Change. 

3-Methylthiofentanyl ...................................................................................................................... 2 g No Change. 

3,4-Methylenedioxyamphetamine (MDA) ...................................................................................... 22 g No Change. 

3,4-Methylenedioxy-N-ethylamphetamine (MDEA) ....................................................................... 15 g No Change. 

3,4-Methylenedioxymethamphetamine (MDMA) ........................................................................... 22 g No Change. 

3,4,5-Trimethoxyamphetamine ...................................................................................................... 2 g No Change. 

4-Bromo-2,5-dimethoxyamphetamine (DOB) ................................................................................ 2 g No Change. 

4-Bromo-2,5-dimethoxyphenethylamine (2–CB) ........................................................................... 2 g No Change. 

4-Methoxyamphetamine ................................................................................................................ 77 g No Change. 

4-Methylaminorex .......................................................................................................................... 2 g No Change. 

4-Methyl-2,5-dimethoxyamphetamine (DOM) ............................................................................... 2 g No Change. 

5-Methoxy-3,4-methylenedioxyamphetamine ................................................................................ 2 g No Change. 

5-Methoxy-N,N-diisopropyltryptamine ........................................................................................... 2 g No Change. 

Acetyl-alpha-methylfentanyl .......................................................................................................... 2 g No Change. 

Acetyldihydrocodeine .................................................................................................................... 2 g No Change. 

Acetylmethadol .............................................................................................................................. 2 g No Change. 

Allylprodine .................................................................................................................................... 2 g No Change. 

Alphacetylmethadol ....................................................................................................................... 2 g No Change. 

Alpha-ethyltryptamine .................................................................................................................... 2 g No Change. 

Alphameprodine ............................................................................................................................ 2 g No Change. 

Alphamethadol ............................................................................................................................... 2 g No Change. 

Alpha-methylfentanyl ..................................................................................................................... 2 g No Change. 

Alpha-methylthiofentanyl ............................................................................................................... 2 g No Change. 

Alpha-methyltryptamine (AMT) ...................................................................................................... 2 g No Change. 

Aminorex ....................................................................................................................................... 2 g No Change. 

Benzylmorphine ............................................................................................................................. 2 g No Change. 

Betacetylmethadol ......................................................................................................................... 2 g No Change. 

Beta-hydroxy-3-methylfentanyl ...................................................................................................... 2 g No Change. 

Beta-hydroxyfentanyl ..................................................................................................................... 2 g No Change. 

Betameprodine .............................................................................................................................. 2 g No Change. 

Betamethadol ................................................................................................................................ 2 g No Change. 

Betaprodine ................................................................................................................................... 2 g No Change. 

Bufotenine ..................................................................................................................................... 3 g No Change. 

Cathinone ...................................................................................................................................... 4 g No Change. 

Codeine-N-oxide ............................................................................................................................ 602 g No Change. 

Diethyltryptamine ........................................................................................................................... 2 g No Change. 

Difenoxin ........................................................................................................................................ 3,000 g 50 g. 

Dihydromorphine ........................................................................................................................... 3,608,000 g No Change. 

Dimethyltryptamine ........................................................................................................................ 7 g No Change. 

Gamma-hydroxybutyric acid .......................................................................................................... 3,000,000 g 5,434,000 g. 

Heroin ............................................................................................................................................ 20 g No Change. 

Hydromorphinol ............................................................................................................................. 2 g No Change. 

Hydroxypethidine ........................................................................................................................... 2 g No Change. 

Ibogaine ......................................................................................................................................... 5 g No Change. 

Lysergic acid diethylamide (LSD) ................................................................................................. 16 g No Change. 

Marihuana ...................................................................................................................................... 21,000 g No Change. 

Mescaline ...................................................................................................................................... 5 g No Change. 

Methaqualone ................................................................................................................................ 10 g No Change. 

Methcathinone ............................................................................................................................... 4 g No Change. 

Methyldihydromorphine ................................................................................................................. 2 g No Change. 

Morphine-N-oxide .......................................................................................................................... 605 g No Change. 

N-Benzylpiperazine ....................................................................................................................... 2 g No Change. 

N,N-Dimethylamphetamine ........................................................................................................... 2 g No Change. 

N-Ethylamphetamine ..................................................................................................................... 2 g No Change. 

N-Hydroxy-3,4-methylenedioxyamphetamine ............................................................................... 2 g No Change. 

Noracymethadol ............................................................................................................................ 2 g No Change. 

Norlevorphanol .............................................................................................................................. 52 g No Change. 

Normethadone ............................................................................................................................... 2 g No Change. 

Normorphine .................................................................................................................................. 18 g No Change. 

Para-fluorofentanyl ........................................................................................................................ 2 g No Change. 

Phenomorphan .............................................................................................................................. 2 g No Change. 

Pholcodine ..................................................................................................................................... 2 g No Change. 

Psilocybin ...................................................................................................................................... 2 g No Change. 

Psilocyn ......................................................................................................................................... 2 g No Change. 

Tetrahydrocannabinols .................................................................................................................. 393,000 g No Change. 

Thiofentanyl ................................................................................................................................... 2 g No Change. 

Tilidine ........................................................................................................................................... 10 g No Change. 

Trimeperidine ................................................................................................................................. 2 g No Change. 

mstockstill on DSK4VPTVN1PROD with NOTICES

Federal Register / Vol. 76, No. 178 / Wednesday, September 14, 2011 / Notices 56813 

Basic class—schedule II 

Previously established initial 

2011 quotas 

Proposed 

adjusted 

2011 quotas 

1-Phenylcyclohexylamine .............................................................................................................. 2 g No Change. 

1-Piperdinocyclohexanecarbonitrile ............................................................................................... 2 g No Change. 

4-Anilino-N-phenethyl-4-piperidine (ANPP) ................................................................................... 2,500,000 g 1,800,000 g. 

Alfentanil ........................................................................................................................................ 8,000 g 11,600 g. 

Alphaprodine ................................................................................................................................. 2 g No Change. 

Amobarbital ................................................................................................................................... 40,007 g No Change. 

Amphetamine (for conversion) ...................................................................................................... 7,500,000 g 8,500,000 g. 

Amphetamine (for sale) ................................................................................................................. 18,600,000 g 25,300,000 g. 

Cocaine ......................................................................................................................................... 247,000 g 216,000 g. 

Codeine (for conversion) ............................................................................................................... 65,000,000 g No Change. 

Codeine (for sale) .......................................................................................................................... 39,605,000 g No Change. 

Dextropropoxyphene ..................................................................................................................... 92,000,000 g 7 g. 

Dihydrocodeine .............................................................................................................................. 800,000 g 255,000 g. 

Diphenoxylate ................................................................................................................................ 827,000 g 500,000 g. 

Ecgonine ........................................................................................................................................ 83,000 g No Change. 

Ethylmorphine ................................................................................................................................ 2 g No Change. 

Fentanyl ......................................................................................................................................... 1,428,000 g No Change. 

Glutethimide .................................................................................................................................. 2 g No Change. 

Hydrocodone (for sale) .................................................................................................................. 55,000,000 g 59,000,000 g. 

Hydromorphone ............................................................................................................................. 3,455,000 g No Change. 

Isomethadone ................................................................................................................................ 11 g 2 g. 

Levo-alphacetylmethadol (LAAM) ................................................................................................. 3 g No Change. 

Levomethorphan ............................................................................................................................ 5 g 2 g. 

Levorphanol ................................................................................................................................... 10,000 g 3,600 g. 

Lisdexamfetamine ......................................................................................................................... 9,000,000 g 10,400,000 g. 

Meperidine ..................................................................................................................................... 6,600,000 g 5,200,000 g. 

Meperidine Intermediate-A ............................................................................................................ 3 g No Change. 

Meperidine Intermediate-B ............................................................................................................ 7 g No Change. 

Meperidine Intermediate-C ............................................................................................................ 3 g No Change. 

Metazocine .................................................................................................................................... 5 g No Change. 

Methadone (for sale) ..................................................................................................................... 20,000,000 g No Change. 

Methadone Intermediate ............................................................................................................... 26,000,000 g No Change. 

Methamphetamine ......................................................................................................................... 3,130,000 g No Change. 

[750,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 2,331,000 grams for methamphetamine mostly for 

conversion to a schedule III product; and 49,000 grams for methamphetamine (for sale)] 

Methylphenidate ............................................................................................................................ 50,000,000 g 56,000,000 g. 

Morphine (for conversion) ............................................................................................................. 83,000,000 g 70,000,000 g. 

Morphine (for sale) ........................................................................................................................ 39,000,000 g No Change. 

Nabilone ........................................................................................................................................ 10,502 g No Change. 

Noroxymorphone (for conversion) ................................................................................................. 9,000,000 g 7,200,000 g. 

Noroxymorphone (for sale) ........................................................................................................... 401,000 g No Change. 

Opium (powder) ............................................................................................................................. 230,000 g 63,000 g. 

Opium (tincture) ............................................................................................................................. 1,500,000 g 1,000,000 g. 

Oripavine ....................................................................................................................................... 15,000,000 g 8,000,000 g. 

Oxycodone (for conversion) .......................................................................................................... 5,600,000 g No Change. 

Oxycodone (for sale) ..................................................................................................................... 105,500,000 g 98,000,000 g. 

Oxymorphone (for conversion) ...................................................................................................... 12,800,000 g No Change. 

Oxymorphone (for sale) ................................................................................................................ 3,070,000 g No Change. 

Pentobarbital ................................................................................................................................. 28,000,000 g 31,000,000 g. 

Phenazocine .................................................................................................................................. 5 g No Change. 

Phencyclidine ................................................................................................................................ 24 g No Change. 

Phenmetrazine .............................................................................................................................. 2 g No Change. 

Phenylacetone ............................................................................................................................... 8,000,000 g No Change. 

Racemethorphan ........................................................................................................................... 2 g No Change. 

Remifentanil ................................................................................................................................... 2,500 g No Change. 

Secobarbital ................................................................................................................................... 260,002 g 336,002 g. 

Sufentanil ....................................................................................................................................... 7,000 g 5,000 g. 

Tapentadol ..................................................................................................................................... 1,000,000 g 403,000 g. 

Thebaine ........................................................................................................................................ 126,000,000 g 116,000,000 g. 

Aggregate production quotas for all 

other schedule I and II controlled 

substances included in 21 CFR 1308.11 

and 1308.12 remain at zero. 

Analysis for Proposed Aggregate 

Production Quotas for Temporarily 

Scheduled Substances 

The proposed year 2011 aggregate 

production quotas represent those 

quantities of controlled substances that 

may be produced in the United States in 

2011 to provide adequate supplies of 

each substance for estimated medical, 

scientific, research, and industrial needs 

of the United States; lawful export 

requirements; and the establishment 

and maintenance of reserve stocks. 

These quotas do not include imports of 

mstockstill on DSK4VPTVN1PROD with NOTICES

56814 Federal Register / Vol. 76, No. 178 / Wednesday, September 14, 2011 / Notices 

controlled substances for use in 

industrial processes. 

In determining the year 2011 

aggregate production quotas for the five 

temporarily scheduled controlled 

substances listed below, the 

Administrator considered the following 

factors, in accordance with 21 U.S.C. 

826(a) and 21 CFR 1303.11: Total 

estimated net disposal of each substance 

by all manufacturers; total estimated 

inventories of the class and of all 

substances manufactured in the class; 

projected demand for such class as 

indicated by procurement quotas 

requested pursuant to 21 CFR 1303.12; 

and other factors affecting medical, 

scientific, research, and industrial needs 

of the United States and lawful export 

requirements. 

DEA has received applications for 

registration and quota for the 

temporarily scheduled controlled 

substances listed below. In examining 

the information provided by the 

applicant(s), along with other 

information, DEA finds that there is a 

current need for these substances. The 

Administrator therefore proposes that 

the year 2011 aggregate production 

quotas for the following controlled 

substances, expressed in grams of 

anhydrous acid or base, be established 

as follows: 

Basic class–schedule I 

Proposed 

2011 

quotas 

1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH–200) .................................................................................................................... 45 g 

1-Butyl-3-(1-naphthoyl)indole (JWH–073) ................................................................................................................................................. 45 g 

1-Pentyl-3-(1-naphthoyl)indole (JWH–018) ............................................................................................................................................... 45 g 

5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP–47,497) .......................................................................................... 68 g 

5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol; CP–47,497 C8 homologue) ............................... 53 g 

Pursuant to 21 CFR part 1303, the 

Administrator may adjust the 2011 

aggregate production quotas and 

individual manufacturing quotas 

allocated for the year. 

Comments 

Pursuant to 21 CFR 1303.11 and 

1303.13, any interested person may 

submit written comments on or 

objections to these proposed 

determinations. Based on comments 

received in response to this Notice, the 

Administrator may hold a public 

hearing on one or more issues raised. In 

the event the Administrator decides in 

her sole discretion to hold such a 

hearing, the Administrator will publish 

a notice of any such hearing in the 

Federal Register. After consideration of 

any comments and after a hearing, if one 

is held, the Administrator will publish 

in the Federal Register a Final Order 

determining any adjustment of the 

aggregate production quota. 

Dated: September 2, 2011. 

Michele M. Leonhart, 

Administrator. 

[FR Doc. 2011–23498 Filed 9–13–11; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF LABOR 

Office of the Secretary 

Agency Information Collection 

Activities; Submission for OMB 

Review; Comment Request; Enhanced 

Traditional Jobs Demonstration 

ACTION: Notice. 

SUMMARY: The Department of Labor 

(DOL) is submitting the Employment 

and Training Administration (ETA) 

sponsored and proposed information 

collection request (ICR) titled, 

‘‘Enhanced Traditional Jobs 

Demonstration,’’ to the Office of 

Management and Budget (OMB) for 

review and approval for use in 

accordance with the Paperwork 

Reduction Act (PRA) of 1995 (44 U.S.C. 

3501 et seq.). 

DATES: Submit comments on or before 

October 14, 2011. 

ADDRESSES: A copy of this ICR with 

applicable supporting documentation; 

including a description of the likely 

respondents, proposed frequency of 

response, and estimated total burden 

may be obtained from the RegInfo.gov 

Web site, http://www.reginfo.gov/ 

public/do/PRAMain, on the day 

following publication of this notice or 

by contacting Michel Smyth by 

telephone at 202–693–4129 (this is not 

a toll-free number) or sending an e-mail 

to DOL_PRA_PUBLIC@dol.gov. 

Submit comments about this request 

to the Office of Information and 

Regulatory Affairs, Attn: OMB Desk 

Officer for the Department of Labor, 

Employment and Training 

Administration (ETA), Office of 

Management and Budget, Room 10235, 

Washington, DC 20503, Telephone: 

202–395–6929/Fax: 202–395–6881 

(these are not toll-free numbers), e-mail: 

OIRA_submission@omb.eop.gov. 

FOR FURTHER INFORMATION CONTACT: 

Michel Smyth by telephone at 202–693– 

4129 (this is not a toll-free number) or 

by e-mail at 

DOL_PRA_PUBLIC@dol.gov. 

SUPPLEMENTARY INFORMATION: This ICR 

would implement Enhanced 

Transitional Jobs Demonstration 

reporting and recordkeeping 

requirements. This reporting structure 

features standardized data collection for 

program participants and quarterly 

narrative, performance, and 

management information system report 

formats. All data collection and 

reporting will be done by grantee 

organizations (state or local government 

or faith-based and community 

organizations) or their sub-grantees. 

This information collection is subject 

to the PRA. A Federal agency generally 

cannot conduct or sponsor a collection 

of information, and the public is 

generally not required to respond to an 

information collection, unless it is 

approved by the OMB under the PRA 

and displays a currently valid OMB 

Control Number. In addition, 

notwithstanding any other provisions of 

law, no person shall generally be subject 

to penalty for failing to comply with a 

collection of information if the 

collection of information does not 

display a valid OMB Control Number. 

See 5 CFR 1320.5(a) and 1320.6. For 

additional information, see the related 

notice published in the Federal Register 

on June 1, 2011 (76 FR 31639). 

Interested parties are encouraged to 

send comments to the OMB, Office of 

Information and Regulatory Affairs at 

the address shown in the ADDRESSES

section within 30 days of publication of 

this notice in the Federal Register. In 

order to help ensure appropriate 

consideration, comments should 

mention OMB ICR Reference Number 

201108–1205–002. The OMB is 

particularly interested in comments 

that: 

• Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

mstockstill on DSK4VPTVN1PROD with NOTICES